Artal Group S.A. Argenx Se Transaction History

Artal Group S.A.

$214 Million
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$338.91 - $506.01 $39.4 Million - $58.9 Million	116,388 New	116,388 $44.3 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $85.8 Million - $98.9 Million	-250,000 Reduced 62.5%	150,000 $53 Million
Q2 2022 Aug 11, 2022	SELL	$269.58 - $378.88 $50.5 Million - $71 Million	-187,500 Reduced 31.91%	400,000 $152 Million
Q1 2022 May 12, 2022	BUY	$254.45 - $351.06 $22.3 Million - $30.7 Million	87,500 Added 17.5%	587,500 $185 Million
Q4 2021 Feb 11, 2022	SELL	$272.01 - $353.03 $21 Million - $27.3 Million	-77,308 Reduced 13.39%	500,000 $175 Million
Q3 2021 Nov 12, 2021	BUY	$295.0 - $350.58 $22.8 Million - $27.1 Million	77,308 Added 15.46%	577,308 $174 Million
Q2 2021 Aug 13, 2021	BUY	$257.11 - $319.92 $12.9 Million - $16 Million	50,000 Added 11.11%	500,000 $151 Million
Q1 2021 May 14, 2021	BUY	$268.3 - $380.31 $40.2 Million - $57 Million	150,000 Added 50.0%	450,000 $124 Million
Q4 2020 Feb 11, 2021	SELL	$248.13 - $308.36 $6 Million - $7.46 Million	-24,200 Reduced 7.46%	300,000 $88.2 Million
Q3 2020 Nov 13, 2020	SELL	$215.51 - $272.51 $27.1 Million - $34.3 Million	-125,800 Reduced 27.96%	324,200 $85.1 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $3.19 Million - $5.82 Million	-25,000 Reduced 5.26%	450,000 $101 Million
Q1 2020 May 14, 2020	BUY	$108.83 - $165.23 $13.6 Million - $20.7 Million	125,000 Added 35.71%	475,000 $62.6 Million
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $16 Million - $24.6 Million	150,000 Added 75.0%	350,000 $56.2 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $2.27 Million - $3.01 Million	-20,000 Reduced 9.09%	200,000 $22.8 Million
Q2 2019 Aug 09, 2019	BUY	$115.0 - $141.58 $2.3 Million - $2.83 Million	20,000 Added 10.0%	220,000 $31.1 Million
Q1 2019 May 10, 2019	SELL	$98.85 - $134.59 $6.92 Million - $9.42 Million	-70,000 Reduced 25.93%	200,000 $25 Million
Q4 2018 Feb 11, 2019	BUY	$63.81 - $109.82 $5.42 Million - $9.33 Million	85,000 Added 45.95%	270,000 $25.9 Million
Q3 2018 Nov 09, 2018	BUY	$75.5 - $96.63 $2.64 Million - $3.38 Million	35,000 Added 23.33%	185,000 $14 Million
Q1 2018 May 10, 2018	SELL	$56.95 - $85.19 $2.85 Million - $4.26 Million	-50,000 Reduced 25.0%	150,000 $12.1 Million
Q4 2017 Feb 09, 2018	BUY	$22.57 - $63.56 $3.29 Million - $9.26 Million	145,663 Added 268.07%	200,000 $12.6 Million
Q3 2017 Nov 08, 2017	BUY	$19.81 - $22.61 $1.08 Million - $1.23 Million	54,337	54,337 $1.23 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

Price T Rowe Associates Inc Baltimore, MD

5.82M
Shares

$3.28 Billion
0.36% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.51M
Shares

$1.98 Billion
2.99% of portfolio
Janus Henderson Group PLC London, X0

2.48M
Shares

$1.4 Billion
0.72% of portfolio
Capital World Investors Los Angeles, CA

1.7M
Shares

$959 Million
0.15% of portfolio
Avoro Capital Advisors LLC New York, NY

1.24M
Shares

$699 Million
10.11% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account